Caffeic Acid Inhibits Colitis In A Mouse Model: Is A Drug-metabolizing Gene Crucial?

The normalization of CYP4B1 by caffeic acid treatment was associated with significant lessening of colitic damage, assessed by examining colon histopathology. In comparison with rutin, an anti-inflammatory flavonoid and hypoxoside extract, a botanical known as African potato previously shown to protect against colitis, all three compounds had anti-inflammatory effects, suppressing myeloperoxidase, IL-17 and iNOS and increasing IL-4, known factors associated with inflammation responses.

But only caffeic acid protected against the dextran sulfate sodium induced colitis. Its novel mechanism related to CYP4B1 is being studied further. The research team, Zhong Ye, a graduate student in Toxicology, along with Microbiology graduate students Zhiping Liu and Abigail Henderson, Visiting Scientist Kwangwon Lee, Korea University, Dr. Michael Wannemuehler, Veterinary Microbiology, Dr. Jesse Hostetter, a veterinary pathologist, and Dr. Suzanne Hendrich, Toxicologist and Nutritionist, performed studies in 8 week old mice fed the various dietary components and then exposed to dextran sulfate sodium in a mildly irritating dose to induce colitis. Dr. Hendrich noted that "this study of caffeic acid will help us to advance studies of botanicals and plant foods with respect to their ability and mechanisms of inhibiting colitis, and perhaps colon cancer, because colitis increases risk for this disease".

In summary, normalization of expression of CYP4B1, a drug metabolizing enzyme possibly related to reversal of inflammatory damage was a hallmark of the efficacy of caffeic acid, a component found widely in plant foods in the human diet, to inhibit intestinal tissue damage in a mouse model commonly used to simulate colitis. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "The article by Hendrich and colleagues may help in the future design of more effective treatments to prevent or diminish colitis".